The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
Open accessAbstract
Redirecting T cells to attack cancer using engineered chimeric receptors provides powerful new therapeutic capabilities. But the effectiveness of therapeutic T cells is constrained by the endogenous T cell response: certain facets of natural response programs can be toxic, whereas other responses, such as the ability to overcome tumor immunosuppression, are absent. Thus, the efficacy and safety of therapeutic cells could be improved if we could custom sculpt immune cell responses. Synthetic Notch receptors induce transcriptional activation in response to recognition of user-specified antigens. We show that synNotch receptors can be used to sculpt custom response programs in primary T cells: they can drive a la carte cytokine secretion profiles, biased T cell differentiation, and local delivery of non-native therapeutic payloads, such as antibodies, in response to antigen. SynNotch T cells can thus be used as a general platform to recognize and remodel local microenvironments associated with diverse diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312
Regulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Notch signalling: a simple pathway becomes complex
Bray, S. J. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2009 · Cited by 2,620
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Control of adaptive immunity by the innate immune system
Iwasaki, A., & Medzhitov, R. (2015) · Nature Immunology · doi:10.1038/ni.3123 · Cited by 2,160 · cited 1×
“The specific cytokine profile is critical for eradicating pathogens and tumors (Dranoff, 2004; Iwasaki and Medzhitov, 2015).”
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Regulation and Functions of the IL-10 Family of Cytokines in Inflammation and Disease
Ouyang, W., Rutz, S., Crellin, N. K., Valdez, P. A., & Hymowitz, S. G. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101312 · Cited by 1,925
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
Mechanisms Underlying Lineage Commitment and Plasticity of Helper CD4 + T Cells
O’Shea, J. J., & Paul, W. E. (2010) · Science · doi:10.1126/science.1178334 · Cited by 1,336
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors
Morsut, L., Roybal, K. T., Xiong, X., Gordley, R. M., Coyle, S. M., Thomson, M., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.01.012 · Cited by 1,000
Self-citationPrecision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
Roybal, K. T., Rupp, L. J., Morsut, L., Walker, W. J., McNally, K. A., Park, J. S., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.01.011 · Cited by 1,000
Self-citationLamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 857
A Ligand-Induced Extracellular Cleavage Regulates γ-Secretase-like Proteolytic Activation of Notch1
Mumm, J. S., Schroeter, E. H., Saxena, M. T., Griesemer, A., Tian, X., Pan, D. J., Ray, W. J., & Kopan, R. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80416-5 · Cited by 853
Memory T Cell Subsets, Migration Patterns, and Tissue Residence
Mueller, S. N., Gebhardt, T., Carbone, F. R., & Heath, W. R. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095954 · Cited by 839
The TRAIL apoptotic pathway in cancer onset, progression and therapy
Johnstone, R. W., Frew, A. J., & Smyth, M. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2465 · Cited by 834
Nuclear Access and Action of Notch In Vivo
Struhl, G., & Adachi, A. (1998) · Cell · doi:10.1016/s0092-8674(00)81193-9 · Cited by 733
Stress, Inflammation, and Defense of Homeostasis
Chovatiya, R., & Medzhitov, R. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.03.030 · Cited by 704
O'Shea, J. J., Ma, A., & Lipsky, P. (2002) · Nature Reviews Immunology · doi:10.1038/nri702 · Cited by 675
N OTCH AND P RESENILIN: Regulated Intramembrane Proteolysis Links Development and Degeneration
Selkoe, D., & Kopan, R. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.041002.131334 · Cited by 636
Liu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E. C., Cogdill, A. P., Li, N., Ramones, M., Granda, B., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0159 · Cited by 565
Design and development of therapies using chimeric antigen receptor‐expressing T cells
Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K. (2014) · Immunological Reviews · doi:10.1111/imr.12131 · Cited by 508
A robust pipeline for rapid production of versatile nanobody repertoires
Fridy, P. C., Li, Y., Keegan, S., Thompson, M. K., Nudelman, I., Scheid, J. F., Oeffinger, M., Nussenzweig, M. C., Fenyö, D., Chait, B. T., et al. (2014) · Nature Methods · doi:10.1038/nmeth.3170 · Cited by 499
Getting TRAIL back on track for cancer therapy
Lemke, J., von Karstedt, S., Zinngrebe, J., & Walczak, H. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.81 · Cited by 457
Strategies for use of IL‐10 or its antagonists in human disease
O'Garra, A., Barrat, F. J., Castro, A. G., Vicari, A., & Hawrylowicz, C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00635.x · Cited by 452
The PDL1-PD1 Axis Converts Human T H 1 Cells into Regulatory T Cells
Amarnath, S., Mangus, C. W., Wang, J. C. M., Wei, F., He, A., Kapoor, V., Foley, J. E., Massey, P. R., Felizardo, T. C., Riley, J. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003130 · Cited by 446
Cell-Based Therapeutics: The Next Pillar of Medicine
Fischbach, M. A., Bluestone, J. A., & Lim, W. A. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005568 · Cited by 419
Self-citationMolecular determinants of response to TRAIL in killing of normal and cancer cells.
Kim, K., Fisher, M. J., Xu, S., & El‐Deiry, W. S. (2000) · PubMed · Cited by 376
Mechanical Allostery: Evidence for a Force Requirement in the Proteolytic Activation of Notch
Gordon, W. R., Zimmerman, B., He, L., Miles, L. J., Huang, J., Tiyanont, K., McArthur, D. G., Aster, J. C., Perrimon, N., Loparo, J. J., et al. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.05.004 · Cited by 374
Structural basis for autoinhibition of Notch
Gordon, W. R., Vardar-Ulu, D., Histen, G., Sanchez-Irizarry, C., Aster, J. C., & Blacklow, S. C. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1227 · Cited by 372
Blinatumomab: A historical perspective
Nagorsen, D., Kufer, P., Baeuerle, P. A., & Bargou, R. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.013 · Cited by 355
Chimeric Antigen Receptor Therapy for Cancer
Barrett, D. M., Singh, N., Porter, D. L., Grupp, S. A., & June, C. H. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-060512-150254 · Cited by 349
Functional optimization of gene clusters by combinatorial design and assembly
Smanski, M. J., Bhatia, S., Zhao, D., Park, Y., B A Woodruff, L., Giannoukos, G., Ciulla, D., Busby, M., Calderon, J., Nicol, R., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3063 · Cited by 340
Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
Gill, S., & June, C. H. (2015) · Immunological Reviews · doi:10.1111/imr.12243 · Cited by 320
Secretory Mechanisms in Cell-Mediated Cytotoxicity
Stinchcombe, J. C., & Griffiths, G. M. (2007) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.23.090506.123521 · Cited by 312
Immunotherapy and tumor microenvironment
Tang, H., Qiao, J., & Fu, Y.-X. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.009 · Cited by 308
Zhao, Y., Wang, Q. J., Yang, S., Kochenderfer, J. N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S. A., & Morgan, R. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900447 · Cited by 293
Adoptive Immunotherapy for Cancer or Viruses
Maus, M. V., Fraietta, J. A., Levine, B. L., Kalos, M., Zhao, Y., & June, C. H. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120136 · Cited by 264
Designing customized cell signalling circuits
Lim, W. A. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2904 · Cited by 257
Self-citationThe Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy
Miller, J. F. A. P., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.007 · Cited by 245
Vaccine adjuvants as potential cancer immunotherapeutics
Temizoz, B., Kuroda, E., & Ishii, K. J. (2016) · International Immunology · doi:10.1093/intimm/dxw015 · Cited by 227
Engineering lymphocyte subsets: tools, trials and tribulations
June, C. H., Blazar, B. R., & Riley, J. L. (2009) · Nature Reviews Immunology · doi:10.1038/nri2635 · Cited by 204
Indirect evidence for Delta-dependent intracellular processing of Notch in Drosophila embryos
Lecourtois, M., & Schweisguth, F. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70300-8 · Cited by 197
Toxicity management for patients receiving novel T-cell engaging therapies
Barrett, D. M., Teachey, D. T., & Grupp, S. A. (2013) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000043 · Cited by 144
The microanatomy of T‐cell responses
Lämmermann, T., & Sixt, M. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00592.x · Cited by 131
Sundrud, M. S., Grill, S. M., Ni, D., Nagata, K., Alkan, S. S., Subramaniam, A., & Unutmaz, D. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3542 · Cited by 112
Tailored Immune Responses: Novel Effector Helper T Cell Subsets in Protective Immunity
Kara, E. E., Comerford, I., Fenix, K. A., Bastow, C. R., Whyte, C. E., McKenzie, D. R., & McColl, S. R. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003905 · Cited by 88
Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display
Nair, P. M., Flores, H., Gogineni, A., Marsters, S. A., Lawrence, D. A., Kelley, R. F., Ngu, H., Sagolla, M. S., Kömüves, L. G., Bourgon, R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418962112 · Cited by 80
Leigh, N. D., Bian, G., Ding, X., Liu, H., Aygun‐Sunar, S., Burdelya, L. G., Gudkov, A. V., & Cao, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085587 · Cited by 63
Anderson, R. W., Macdonald, I., Corbett, T., Hacking, G., Lowdell, M. W., & Prentice, H. G. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.9-1125 · Cited by 61
Lacy, M. Q., Jacobus, S. J., Blood, E., Kay, N. E., Rajkumar, S. V., & Greipp, P. R. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.01.020 · Cited by 57
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.
Magee, M. S., & Snook, A. E. (2014) · PubMed · Cited by 48
Park, S.-J., Kim, M., Kim, H.-B., Sohn, H., Bae, J.-H., Kang, C., & Kim, S. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.02.024 · Cited by 27
Cited by
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,080
Self-citationNotch Signaling in Development, Tissue Homeostasis, and Disease
Siebel, C., & Lendahl, U. (2017) · Physiological Reviews · doi:10.1152/physrev.00005.2017 · Cited by 978
TGF-β signaling in health and disease
Massagué, J., & Sheppard, D. (2023) · Cell · doi:10.1016/j.cell.2023.07.036 · Cited by 890
Treg cell-based therapies: challenges and perspectives
Raffin, C., Vo, L. T., & Bluestone, J. A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0232-6 · Cited by 720
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 702
Metadata
- Authors
- Roybal, K. T., Williams, J. Z., Morsut, L., Rupp, L. J., Kolinko, I., Choe, J. H., Walker, W. J., McNally, K. A., & Lim, W. A.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 167
- Issue
- 2
- Pages
- 419-432.e16
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2526887159
- Cited by
- 721
- References
- 64
- FWCI
- 27.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.